A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 20 Sep 2017
At a glance
- Drugs FAZ 053 (Primary) ; PDR 001 (Primary)
- Indications Breast cancer; Endometrial cancer; Non-small cell lung cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharmaceuticals
- 30 Jun 2017 Planned End Date changed from 5 Oct 2019 to 6 Oct 2019.
- 30 Jun 2017 Planned primary completion date changed from 5 Oct 2019 to 6 Oct 2019.
- 16 Nov 2016 Planned End Date changed from 1 Feb 2019 to 1 Oct 2019.